

















RESPIRATORY MEDICATIONS FOR INHALATION AVAILABLE IN CANADA PRODUCTS & DEVICES







Table 1: Inhalers – Availability, Device Type and Dose Counter Features


Drug Name Generic (Brand Name)	Image	Availability Dose per Inhalation; # of doses/container	Device type	Dose Counter Features	Indication	ODB Coverage
Bronchodilators						
Short-acting beta₂-agonist (SABA)						
Salbutamol, (Ventolin Diskus [®])		200 mcg; 60	Diskus	Dose counter counts down from 60 to 1. The last 5 numbers are in red.	Asthma COPD	No
Salbutamol (Ventolin HFA [®])		100 mcg; 200	MDI	No dose counter	Asthma COPD	Yes
Salbutamol (Apo-Salbutamol HFA [®])		100 mcg; 200	MDI	No dose counter	Asthma COPD	Yes
Salbutamol (Teva-Salbutamol HFA [®])		100 mcg; 200	MDI	No dose counter	Asthma COPD	Yes
Salbutamol HFA (Sanis)		100 mcg; 200	MDI	No dose counter	Asthma COPD	Yes





Terbutaline, Bricanyl®		500 mcg; 100	Turbuhaler	A red mark shows in the window underneath the mouthpiece when 20 doses are left. When the red mark reaches the bottom of the window, the device is empty.	Asthma COPD	Yes
Long-acting beta₂-agonist (LABA) 12-hour acting						
Formoterol, (Oxeze®)		6 or 12 mcg; 60	Turbuhaler	A red mark shows in the window underneath the mouthpiece when 20 doses are left. When the red mark reaches the bottom of the window.	Asthma (as add-on to ICS)	Asthma LU CODE 132 Not a benefit for COPD
Salmeterol, (Serevent Diskus®)		50 mcg; 60	Diskus	Dose counter counts down from 60 to 1. The last 5 numbers are in red.	Asthma COPD	Asthma LU CODE 132 COPD LU CODE 391
Long acting beta₂-agonist (LABA) 24-hour acting. No single entity products in Canada (24-hour acting LABAs are listed in the combination LAMA/LABA products below)						
Blank						






Short-acting muscarinic antagonist (SAMA) (anticholinergic)						
Ipratropium bromide, Atrovent HFA®		20 mcg; 200	MDI	No dose counter	COPD	Yes
Combination Products (SAMA/SABA)						
Ipratropium/salbutamol, Combivent® Respimat®		20/100 mcg 60 and 120	Respimat SMI	Pointer indicates approximate amount remaining	COPD	No
Long-acting muscarinic antagonist (LAMA) (anticholinergic)						
Acclidinium bromide, Tudorza® Genuair®	Note: Pressair image shown 	400 mcg; 30 and 60	Genuair	Dose counter counts down by 10 from 60 to zero. A red strip band appears in the dose counter window indicating time to obtain a new inhaler. When preparing the last dose, the actuation button will not return to its upper position.	COPD	Yes
Glycopyrronium bromide, Seebri® Breezhaler®		50 mcg; 10 and 30	Breezhaler	No dose counter (capsule inserted into the Breezhaler device)	COPD	Yes

Drug Name Generic (Brand Name)	Image	Availability Dose per Inhalation; # of doses/container	Device type	Dose Counter Features	Indication	ODB Coverage
Long-acting muscarinic antagonist (LAMA) (anticholinergic), continued						
Tiotropium bromide, Spiriva®		18 mcg; 10 and 30, 30 refill	Handihaler	No dose counter (capsule inserted into the Handihaler device)	COPD	Yes
Tiotropium bromide, Lupin-Tiotropium®		18 mcg; 10 and 30, 30 refill	LupinHaler	No dose counter (capsule inserted into the Handihaler device)	COPD	Yes
Tiotropium, Spiriva® Respimat®		2.5 mcg; 28 and 60	Respimat SMI	Pointer indicates approximate amount remaining	COPD Asthma	Yes Yes
Umeclidinium bromide, Incruse® Ellipta®		62.5 mcg; 7 and 30	Ellipta	Dose counter counts down by one; when fewer than 10 doses are left, half of the dose counter shows red (as a reminder to refill prescription). After you have inhaled the last dose, half of the dose counter shows red and the number 0 is displayed. Your inhaler is now empty. If you open the cover after this, the dose counter will change from half red to completely red. Discard when the dose counter reads "0", or 6 weeks after removal from foil tray, whichever comes first.	COPD	Yes

Combination products (LAMA/LABA)						
Acclidinum/formoterol, Duaklir Genuair®		LAMA/LABA 400/12 mcg; 60	Genuair	Dose counter counts down by 10 from 60 to zero. A red strip band appears in the dose counter window indicating time to obtain a new inhaler. When preparing the last dose, the actuation button will not return to its upper position.	COPD	LU CODE 459
Indacaterol/ glycopyrronium, Ultibro® Breezhaler®		LABA/LAMA 110/ 50 mcg; 6 and 30	Breezhaler	No dose counter (capsule inserted into the Breezhaler device)	COPD	COPD LU CODE 459
Tiotropium/olodaterol, Inspiroto® Respiimat®		LAMA/LABA 2.5/2.5 mcg 28 and 60	Respiimat SMI	Pointer indicates approximate amount remaining	COPD	COPD LU CODE 459
Umeclidinium/vilanterol, Anoro® Ellipta®		LAMA/LABA 62.5/ 25 mcg; 7 and 30	Ellipta	See Ellipta instructions above	COPD	COPD LU CODE 459
Inhaled corticosteroids (ICS)						
Beclomethasone, (in ethanol), Qvar®		50 or 100 mcg; 100 and 200	MDI	No dose counter	Asthma	Yes
Budesonide, Pulmicort®		100, 200, or 400 mcg; 200	Turbuhaler	A red mark shows in the window underneath the mouthpiece when 20 doses are left. Discard when the red mark reaches the bottom of the window.	Asthma	Yes

Ciclesonide (in ethanol), Alvesco®		100 or 200 mcg; <i>30 and 120</i>	MDI	No dose counter	Asthma	Yes
Fluticasone propionate, Flovent Diskus®		100, 250, or 500 mcg; <i>60</i>	Diskus	Dose counter counts down from 60 to 1. The last 5 numbers are in red.	Asthma	Yes
Fluticasone propionate, Aermony Respiclick®		55, 113, or 232 mcg <i>60</i>	Respiclick	Dose counter counts down from 60 by 2, (ie, 60, 58). Numbers change to red from 20 downward. Discard inhaler when dose counter reaches zero. No priming. Do not use a spacer device.	Asthma	Yes
Fluticasone propionate, Flovent HFA®		50, 125 or 250 mcg; <i>60 and 120</i>	MDI	No dose counter	Asthma	Yes, except for 50 mcg
pms-Fluticasone propionate HFA®		125 or 250 mcg; <i>60 and 120</i>	MDI	No dose counter	Asthma	Yes
APO-Fluticasone propionate HFA®		250 mcg; <i>120</i>	MDI	No dose counter	Asthma	Yes

Fluticasone furoate, Arnuity® Ellipta®		100 or 200 mcg; 14 and 30	Ellipta	See Ellipta instructions above	Asthma	Yes
Drug Name Generic, Brand Name	Image	Availability Dose per Inhalation; # of doses/container	Device type	Dose Counter Features	Indication	ODB Coverage
Inhaled corticosteroids (ICS) continued						
Mometasone, Asmanex®		100, 200 or 400 mcg; 30 – 100 or 400 mcg 60 - 200 or 400 mcg	Twisthaler	Dose counter counts down by one, indicating number of doses remaining. When counter reaches 00, the cap will lock.	Asthma	Yes
Combination products (ICS/LABA)						
Budesonide/formoterol, Symbicort®		100/6 or 200/6 mcg; 120 - 100/6 mcg 60 & 120 - 200/6 mcg	Turbuhaler	Counts down. Every 20 th dose is marked by a number and every 10 th dose by a dash. A 0 on a red background in the middle of the window indicates empty.	Asthma: 100 and 200 COPD: 200	Asthma LU CODE 330 Not covered for COPD
Fluticasone propionate /salmeterol, Advair Diskus®		100/50, 250/50, or 500/50 mcg; 28 and 60	Diskus	Dose counter counts down from 60 to 1. The last 5 numbers are in red. Discard when the dose counter reads "0", or one month after removal from foil tray, whichever comes first.	Asthma: all strengths COPD: 250 and 500	Asthma LU CODE 330 Not covered for COPD

Fluticasone propionate /salmeterol, Advair®		125/25 or 250/25 mcg; 120	MDI	Dose counter shows # puffs remaining	Asthma: all strengths	Asthma LU CODE 330 Not covered for COPD
Fluticasone propionate/salmeterol, pms- Fluticasone/salmeterol DPI®		100/50, 250/50, 500/50 mcg; 60	Diskus device	Dose counter counts down by 1 from 60 to zero. The last 5 numbers are in red. Discard 1 month after opening the foil pouch or when the counter reads "0", whichever comes first.	Asthma: all strengths COPD: 250 and 500	Asthma LU CODE 330 Not covered for COPD
Fluticasone propionate/salmeterol, Wixela Inhub®		100/50, 250/50, 500/50 mcg; 60	Modified Diskus device	Dose counter counts down by one from 60 to zero. A red indicator appears when there are 9 doses or less remaining. The lever will not reach the end of the purple arrows when there are no doses remaining. Discard when the dose counter reads "0" or 30 days after it was removed from the foil pouch, whichever comes first.	Asthma: All strengths COPD: 250 and 500	Asthma LU CODE 330 Not covered for COPD
Fluticasone furoate/vilanterol, Breo® Ellipta®		100/25 or 200/25 mcg; 14 and 30	Ellipta	See Ellipta instructions above	Asthma: 100 and 200 COPD: 100	Asthma LU CODE 330 COPD LU Code 456
Mometasone/indacaterol, Atecura® Breezhaler®		80/150, 160/150, 320/150 mcg 30	Breezhaler	No dose counter (capsule inserted into the Breezhaler device)	Asthma	Asthma LU CODE 626





Mometasone/formoterol, (in ethanol), Zenhale®		100/5 or 200/5 mcg; 60 and 120	MDI	Dose counter shows # puffs remaining	Asthma	Asthma LU CODE 330
Drug Name Generic, Brand Name	Image	Availability Dose per Inhalation; # of doses/container	Device type	Dose Counter Features	Indication	ODB Coverage
Combination products (ICS/LAMA/LABA)						
Budesonide/glycopyrrolate/formoterol fumarate dihydrate, Breztri® Aerosphere®		182/8.2/5.8 mcg 56 and 120	Aerosphere MDI	Dose counter shows # puffs remaining	COPD	COPD LU CODE 638
Fluticasone furoate/umeclidinium/vilanterol, Trelegy® Ellipta®		100/62.5/25 mcg; 200/62.5/25 mcg; 14 and 30	Ellipta	See Ellipta instructions above	COPD: 100 Asthma: 100 and 200	COPD LU CODE 567 Not covered for asthma
Mometasone/glycopyronium/indacaterol Enerzair® Breezhaler®		160/50/150 mcg 30	Breezhaler	No dose counter (capsule inserted into the Breezhaler device)	Asthma	Asthma LU CODE 627

Table 2: Metered Dose Inhalers (pressurized MDI, SMI): Priming Instructions

Drug Name Generic, Brand Name	Initial priming* (releasing spray into the air)	Re-priming* (releasing spray into the air)
Bronchodilators		
Short-acting beta₂-agonist (SABA)		
Salbutamol, Apo-Salbutamol HFA®	4 sprays	4 sprays if not used for 2 weeks
Teva-Salbutamol HFA®	4 sprays	4 sprays if not used for 4 weeks
Salbutamol HFA (Sanis)	4 sprays	4 sprays if not used for more than 5 days
Ventolin HFA®	4 sprays	4 sprays if not used for 4 weeks; 1 puff after cleaning
Short-acting muscarinic antagonist (SAMA) (anticholinergic)		
Ipratropium bromide, Atrovent HFA®	2 sprays	1 spray if not used for more than 3 days
Combination Products (SAMA/SABA)		
Ipratropium/salbutamol, Combivent® Respimat®	Until cloud appears + 3 more times	1 spray if not used for more than 3 days. Full priming if not used for more than 21 days
Long-acting muscarinic antagonist (LAMA) 24-hour acting (anticholinergic)		
Tiotropium, Spiriva® Respimat®	Until cloud appears + 3 more times	1 spray if not used for more than 7 days. Full priming if not used for more than 21 days
Combination Products (LAMA/LABA)		
Tiotropium/olodaterol, Inspiro® Respimat®	Until cloud appears + 3 more times	1 spray if not used for more than 7 days. Full priming if not used for more than 21 days
Inhaled corticosteroids (ICS)		
Beclomethasone (in ethanol), Qvar®	4 sprays	4 sprays if not used for 14 days or more
Ciclesonide (in ethanol), Alvesco®	3 sprays	3 sprays if not used for 7 days or more
Fluticasone propionate, Flovent HFA®	1 spray	1 spray if not used for 7 days or more
pms-Fluticasone propionate HFA®	2 sprays	2 sprays if not used for 7 days or more
APO-Fluticasone propionate HFA®	2 sprays	2 sprays if not used for 7 days or more.
Combination products (ICS/LABA)		
Fluticasone propionate /salmeterol, Advair®	1 spray; repeat until dose counter reads 120	2 sprays if not used for 7 days or more
Mometasone/formoterol, (in ethanol), Zenhale®	4 sprays; dose counter should read 120	4 sprays if not used for 5 days or more
Combination products (ICS/LAMA/LABA)		
Budesonide/glycopyrronium/formoterol fumarate dihydrate, Breztri Aerosphere®	4 puffs, shake the inhaler well before each priming puff.	Re-prime the inhaler after cleaning the actuator, if not used for more than 7 days, or if dropped. Shake the inhaler well and press down on the centre of the dose indicator 2 times to release a total of 2 puffs into the air away from your face.

***Priming a Pressurized MDI:**

Initial priming is recommended before using the inhaler for the first time and re-priming is recommended if the inhaler has not been used for a period of time (as specified in each product's instructions for use). When priming, shake the inhaler and direct the recommended number of test sprays into the air, away from the face.

Shaking a Pressurized MDI before Use:

Shake all pressurized MDIs before use except QVAR® and Respimat® products. QVAR® is formulated as a solution in HFA propellant. Respimat® products are formulated as propellant-free solutions.

Definition of Terms

MDI= pressurized metered dose inhaler eg., devices using an HFA propellant

DPI= dry powder inhaler, eg., Diskus, Ellipta, Turbuhaler, Genuair, Handihaler, Breezhaler, Inhub, Respiclick, Twisthaler, Aerolizer

SMI= soft mist inhaler eg., Respimat

Aerosphere= a brand of pressurized metered dose inhaler

DPIs Approved by Health Canada but not marketed

pms-Fluticasone propionate (DPI) 100, 250, 500 mcg/ inhalation. Supplied: *60 in a Diskus device*

Fluticasone propionate/salmeterol (DPI) Respiclick, Arbesda Respiclick® 55/14, 113/14, 232/14 mcg/inh Supplied: *60*

Budesonide/formoterol (DPI) Turbuhaler, Symbicort Forte Turbuhaler® 400/12 mcg/inh. Supplied: *60*

Lupin-Tiotropium® 18 mcg with LupinHaler. Supplied *10, 30*

MDIs Approved by Health Canada but not marketed

pms-Fluticasone propionate HFA 50 mcg/puff. Supplied:HFA 50 mcg (*120*)

APO-Fluticasone 50, 125 mcg HFA. Supplied: *120*

Zenhale 50/5 strength MDI (HFA) Supplied: *60 and 120*

Olodaterol 2.5 mcg/actuation. (Striverdi Respimat). Supplied *60 actuations*

Formoterol fumarate dihydrate 5.8/ glycopyrronium 8.2 mcg/actuation HFA. Supplied: *120 actuations, AstraZeneca*

Table 3. ODB LU Codes

Code	Description	Period
132	For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.	Indefinite
330	For treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.	Indefinite
391	For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.	Indefinite
343	For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.	Indefinite
456	For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD) who have a history of exacerbations and have had an inadequate response to a long-acting bronchodilator (i.e. LABA or LAMA). Notes: COPD disease severity is based on spirometry, symptoms, and disability.	Indefinite
459	For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD) who have a history of exacerbations and have had an inadequate response to a long-acting bronchodilator (i.e. LABA or LAMA). Notes: COPD disease severity is based on spirometry, symptoms, and disability.	Indefinite
567	For the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis, and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations in patients who require a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA).	Indefinite
626	For once-daily maintenance treatment of asthma in patients aged 12 years and older with reversible obstructive airways disease.	Indefinite
627	For the treatment of asthma in adult patients inadequately controlled with a maintenance combination of a long-acting beta-2 agonist (LABA) and a medium or high dose of an inhaled corticosteroid (ICS), who experienced one or more asthma exacerbations in the previous 12 months.	Indefinite
638	For the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations in patients who require a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA).	Indefinite